Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-7.21%
-7.80%
+0.43%
-0.38%
+7.44%
CLOV
Clover Health
$2.50
Chart
$3.01 (-16.94%)
$3.6 (-30.56%)
$3.72 (-32.80%)
$3.2 (-21.88%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-7.21%
-7.80%
+0.43%
-0.38%
+7.44%
CLOV
Clover Health
Current Price
$2.50
Login to view Clover Health (CLOV) recommendation from the last 90 days from financial news and social media.
Chart
$3.01 (-16.94%)
$3.6 (-30.56%)
$3.72 (-32.80%)
$3.2 (-21.88%)
CLOV Latest Analysis
Healthcare AI Market Explodes 38.5% Annually as Diagnostics Gain FDA Traction. News CommentaryIssued on behalf of Avant Technologies Inc. News Commentary – Research and development of new AI-powered tech is causing a major overhaul in the healthcare sector with experts both and at the same time. Analysts at market.us are forecasting the global AI in healthcare market to hit growing at an explosive 38.5% CAGR along the way. With new technologies getting closer to full FDA approval now one of
Today
Clover Health rises after former CEO buys shares.
Mon Aug 11, 2025
Clover drops despite Q2 beat amid concerns over medical cost trends.
Wed Aug 6, 2025
CLOV Q2 Earnings In Line Stock Falls on Raised Insurance BER View. Clover Healths Q2 revenues rise 34% but raised Insurance BER guidance and margin pressures cause shares to tumble post-earnings.
Wed Aug 6, 2025
Clover Health GAAP EPS of -$0.02 beats by $0.01 revenue of $478M beats by $9.7M.
Tue Aug 5, 2025
Clover Beats Q2 Estimates Stock Drops: Here Are The Details. Healthcare technology company ) is trading lower after reporting second-quarter financial results after market close on Tuesday. CLOV is seeing a decline in price after-hours. The company reported an adjusted net loss of two cents per share beating a Street estimate of ...
Tue Aug 5, 2025
Primary Care Physician Use of Counterpart Assistant Technology Linked to Better Health Outcomes in Patients with Chronic Obstructive Pulmonary Disease. New whitepaper shows that a relationship with a primary care physician (PCP) who uses Counterpart Assistant is correlated with more frequent Chronic Obstructive Pulmonary Disease (COPD) diagnosis increased specialty care and meaningful reductions in hospitalizations (15% lower) and 30-day readmissions (18% lower).WILMINGTON Del. Aug. 04 2025 (GLO
Mon Aug 4, 2025
Counterpart Health Appoints Vicky Bruner as Vice President of Operations to Support Expansion and Customer Execution. WILMINGTON Del. July 29 2025 (GLOBE NEWSWIRE) -- Counterpart Health Inc. (Counterpart) a wholly owned subsidiary of Clover Health Investments Corp. (Nasdaq: CLOV) (Clover Clover Health or the Company) and a leading AI-powered physician-enablement platform today announced the appointment of Vicky Bruner as Vice President of Operations.
Tue Jul 29, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
CLOV Stock trends
CLOV Stock performance
CLOV Stock analysis
CLOV investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings